Brief: Ascletis Pharma Sees HY Net Loss Attributable RMB127.3 Million To RMB132.3 Million
07/08/2024 16:03
Aug 7 (Reuters) - Ascletis Pharma 1672.HK :
* SEES NET LOSS ATTRIBUTABLE RMB127.3 MILLION TO RMB132.3
MILLION
FOR SIX MONTHS
* EXPECTED RESULT DUE TO CONTRACTION OF MARKET DEMAND FOR
RITONAVIR PRODUCT, OTHERS
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026